Abbott

2009/9　 Abbott to Acquire Solvay Pharmaceuticals Business

2010/5 　Abbott Accelerates Emerging Markets Pharmaceutical Leadership With Zydus Cadila Collaboration　　　　

　　　Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business

September 28, 2009　　　　　　　　　　　Solvay release 　　Solvay presentation

　　　　　　　　　　　　　　　　　　　　　　　2009/10/2 Abbott、Solvayの医薬品事業を買収

Abbott to Acquire Solvay Pharmaceuticals Business

・Diversifies Abbott's pharmaceutical products, expanding international growth platform
・Supports long-term strategy to bolster presence in key global emerging markets
・Adds substantial R&D spending capacity to accelerate promising pipeline programs
・Establishes Abbott's presence in the growing global vaccines market
・Provides accretion of approximately $0.10 to ongoing EPS in 2010, accelerating to more than $0.20 by 2012, increasing thereafter

Abbott today announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets. The acquisition also includes full global rights to the fenofibrate 高脂血症治療薬;フィブラート系franchise. Currently Abbott has U.S. rights to fenofibrate and pays royalties to Solvay.

Belgium-based Solvay Pharmaceuticals will add more than $3 billion in annual sales, the majority outside the U.S. Solvay has significant presence and infrastructure in key high-growth emerging markets, including Eastern Europe and Asia. Emerging markets are growing faster and increasing in importance due to demographics, rising incomes and expanded treatment of chronic disease.

The acquisition will also add approximately $500 million to Abbott's annual pharmaceutical R&D investment, providing Abbott with the opportunity to further accelerate near and long-term pharmaceutical growth.

"The acquisition of Solvay Pharmaceuticals further diversifies our pharmaceutical portfolio, expands our presence in key high-growth emerging markets, enhances our investment in R&D and accelerates our long-term earnings-per-share growth outlook," said Miles D. White, chairman and chief executive officer, Abbott.

"In anticipation of future market needs, we are ensuring we have the technologies, products, infrastructure and reach to serve patients globally and continue to deliver sustainable industry-leading growth. This acquisition, as well as the others we've announced this year all contribute to achieving that long-term goal," said Mr. White.

"With this transaction Solvay Pharmaceuticals has found a new strong home, within a respected company with a solid and committed position in the industry," comments Christian Jourquin, chief executive officer, Solvay.

Solvay's pharmaceutical portfolio complements Abbott's presence and expertise in specialty markets such as cardiovascular disease, neuroscience and gastroenterology. Solvay has treatments for Parkinson's disease, Ménière's disease (abnormality of the inner ear), vertigo, and irritable bowel syndrome. Solvay also offers products to treat men's and women's hormonal health, and exocrine pancreatic insufficiency (inability to properly digest food), which is associated with several underlying conditions including cystic fibrosis and chronic pancreatitis.

The acquisition also includes Solvay's vaccines business, which will provide Abbott entry into the expanding global vaccines market. Solvay has a small molecular diagnostics unit that will become part of Abbott's diagnostics organization upon the transaction close.

"Abbott's international pharmaceutical business has grown significantly over the past several years, driven by specialty products in developed markets," said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott. "In emerging markets where chronic disease is being treated more aggressively, the combined Abbott and Solvay portfolio of branded generics expands the global reach of these medicines. Solvay's business will also give us a platform to enter the attractive global vaccines market."

Financial Highlights

The transaction will be approximately $0.10 accretive to ongoing earnings per share in 2010, accelerating to more than $0.20 by 2012, increasing thereafter, all before one-time transaction-related items, which will be provided at a later date. These one-time transaction-related items are expected to occur between 2010 and 2012. The transaction also includes payments of up to EUR 300 million if certain sales milestones are met between 2011 and 2013.

Abbott plans to fund the transaction with cash currently on the balance sheet.

This transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the first quarter of 2010. As a result, the deal will have no impact on 2009 ongoing earnings per share. The boards of directors of both companies have approved the proposed acquisition.

Barclays Capital served as an exclusive financial advisor to Abbott on this transaction.

About Solvay Pharmaceuticals

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. These companies seek to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion, and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

ーーーーーーーーーーーーーーーーーー

2009/9/28 Solvay　

Solvay opts for strategic refocus of activities
　　Decision to sell Pharmaceuticals Sector to Abbott

Solvay today announces that its Board of Directors has decided to refocus the activities of the Solvay Group in order to accelerate the implementation of its sustainable and profitable growth strategy and to sell its entire pharmaceutical business to Abbott for a total Entreprise Value of about EUR 5.2 billion. This includes a purchase price of EUR 4.5 billion in cash and additional potential payments of up to EUR 300 million if certain milestones are met between 2011 and 2013. It also includes the assumption of certain liabilities, which Solvay today values at approximately EUR 400 million. This decision is the outcome of the thorough and in-depth analysis and evaluation of the different strategic options for the Pharmaceuticals Sector.
In addition the transaction provides for the transfer of all employees of the pharmaceutical business with their current employment conditions; it also includes customary provisions limiting future exposure of Solvay to its former pharmaceutical activities. This transaction is expected to be closed in the first quarter of 2010, pending the approval by the relevant competition authorities. Solvay will communicate the impact of the transaction on its results when finalized.
After closing of the transaction, Solvay will reinvest the proceeds in organic and sizeable external growth, focused on long term value creation. This will be done by investing in high value-added activities and strategic projects in chemicals and plastics, by continuing the geographical expansion into regions with growth potential and by continuing the development of activities and new products with low energy footprint and which significantly reduce the cyclicality in Solvay’s portfolio of activities. Studies about such reinvestments are ongoing.
“The Board has chosen to give all activities of the Group, Pharmaceuticals and non-Pharmaceuticals, the best possibilities for their future development, and this in the interest of all stakeholders involved”, says Alois Michielsen, Chairman of Solvay’s Board of Directors. “We are building a new refocused Group with the financial means to further accelerate sustainable growth on today’s strong foundations. Our philosophy is unaltered: realizing sustained growth with leading positions and stick to a conservative financial structure. The proceeds from the divestment will be reinvested in external and organic growth with a sharp focus on long term value creation”, adds Christian Jourquin, Chief Executive Officer of Solvay.
“The acquisition by Abbott is an acknowledgment of the performance of the Pharmaceuticals Sector and the strengths and competences of its employees. The Sector will further reinforce Abbott as a leading company in its industry”, comments Werner Cautreels, Group General Manager of the Pharmaceuticals Sector.
Citigroup, Morgan Stanley and Rothschild served as financial advisors to Solvay on this transaction.
Given this announcement, the Solvay Investor Day which was scheduled for 29th September 2009 is cancelled.

Solvay 事業内訳　　

2008年実績（百万ユーロ）

*Recurrent Earnings （経常損益）Before Interest and Tax

Pharmaceuticals

Solvay Pharmaceuticals operates in two key therapeutic fields, in which it undertakes a full range of Research and Development activities:

• Cardiometabolics (including the fenofibrate franchise)
• Neuroscience

These are supplemented by two niche areas in which Solvay is well-established, with extensive know-how:

• Flu vaccines
• Pancreatic enzymes

And by two other commercially important fields where existing products receive management and R&D support:

• Female and male hormone treatments
• Gastroenterology

Sales Breakdown 2008: EUR 2 699 million

-  Cardiometabolics 心臓血管分野　　　812

With the acquisition of Fournier Pharma (in 2005), Solvay Pharmaceuticals has now become the global leader in fenofibrate高脂血症治療薬;フィブラート系, a successful cardiometabolic product for treating raised blood lipids.

Fournier Pharma is an international privately owned research-based pharmaceutical company headquartered in France, with operations in 30 countries.

-  Neuroscience 神経科学　411
　　　　　anti-depressant fluvoxamine、Parkinsons’s disease medication, DUODOPA

-  Flu vaccines137
-  Pancreatic enzymes膵酵素　217
-  Gastroenterology消化器病　 243
-  Female and male hormone treatments  648
-  Others　231

By geographic area
- Europe　46 %

-The Americas 42 %（Nafta　40%、Mercosur2%）

-Asia-Pacific　8 %

-Rest of the world　4 %

May 21, 2010 Abbott

Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business

Strategic action will propel Abbott to No. 1 position with annual sales growth approaching 20 percentin India, expected to exceed $2.5 billion in sales by 2020
Piramal's comprehensive portfolio of market-leading branded generics spans multiple therapeutic areas; combined sales force to become industry's largest in India
India, one of world's fastest-growing markets, generating nearly $8 billion in pharma sales this year; expected to more than double by 2015


Abbott announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion, plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio.
"This strategic action will advance Abbott into the leading market position in India, one of the world's most attractive and rapidly growing markets," said Miles D. White, chairman and chief executive officer, Abbott. "Our strong position in branded generics and growing presence in emerging markets is part of our ongoing diversified pharmaceutical strategy, complementing our market-leading proprietary pharmaceutical offerings and pipeline in developed markets."
"Emerging markets represent one of the greatest opportunities in health care ? not only in pharmaceuticals ? but across all of our business segments. Today, emerging markets represent more than 20 percent of Abbott's total business," said Mr. White.
"With this deal, the combined Healthcare Solutions and Abbott businesses will become the clear market leader in India, with a market share of approximately 7 percent," said Ajay Piramal, chairman, Piramal Group. "This was our collective vision and I am glad that those who are part of Piramal's Healthcare Solutions business will realize this dream."
The Indian Pharmaceutical Market
India is one of the world's fastest-growing pharmaceutical markets, due in large part to branded generics. The market will generate nearly $8 billion in pharmaceutical annual sales this year, a number that is expected to more than double by 2015. Abbott estimates the growth of its Indian pharmaceutical business with Piramal to approach 20 percent annually, with expected sales of more than $2.5 billion by 2020.
Branded generics have significant brand equity in many international markets, providing durable, sustainable franchises for future growth. Piramal markets the products in its Healthcare Solutions business in India only and does not market traditional generic products. Today, branded generics account for 25 percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products.
The Mumbai-based Piramal Healthcare Solutions business has a comprehensive portfolio of branded generics with annual sales expected to exceed $500 million next year in India, and market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience. This business grew 23 percent in 2010 (fiscal year ended March 31,2010), faster than the market in India. Piramal has a strong commercial presence, including the largest sales force in India with a unique model that includes dedicated sales personnel in rural areas inhabited by 70 percent of the population. The combined Abbott and Piramal sales forces will be the industry's largest in India.
Piramal's Healthcare Solutions business will become part of Abbott's newly created, stand-alone Established Products Division. Piramal's Healthcare Solutions business employs more than 5,000 people in India. Abbott, which is celebrating its 100th year in India, has more than 2,500 employees across all of its businesses there.
Abbott's Established Products Strategy
Throughout the past decade, Abbott has built a leading portfolio of branded generics, through its own products as well as those acquired with the 2001 acquisition of Knoll's pharmaceutical business. In 2007, the company established a separate business unit within its international pharmaceutical division dedicated to established products.
Additionally, a new geographic region focused on Russia, India and China was created, which resulted in the doubling of Abbott's growth rate in those countries.
Most recently, the company acquired Solvay Pharmaceuticals, obtaining a diverse branded generics portfolio and providing significant critical mass in key emerging markets.
As a result of these combined actions, Abbott is now among the leading multinational health care companies in numerous emerging markets. Approximately 20 percent of Abbott's pharmaceutical sales today are in emerging markets.
"We have assembled a market-leading branded generics portfolio tailored to the unique needs of emerging markets, strongly positioning Abbott to meet the current and future geographic and market dynamics in pharmaceuticals," said Olivier Bohuon, executive vice president, global pharmaceuticals, Abbott. "Piramal has built a reputation for high-quality, well-known and trusted pharmaceutical brands. We look forward to welcoming the accomplished staff of Piramal's Healthcare Solutions business to Abbott."
Pharmaceutical sales in emerging markets are expected to grow at three times the rate of developed markets and account for 70 percent of pharmaceutical growth over the next several years. This explosive growth is occurring as demographics, rising incomes, modernization of health systems and an increase in the treatment of chronic disease create greater demand for medicines.
Financial Highlights
Under terms of the agreement, Abbott will purchase the assets of Piramal's Healthcare Solutions business for a $2.12 billionup-front payment with payments of $400 million annually for the next four years, beginning in 2011. The transaction will not impact Abbott's ongoing earnings per share guidance in 2010. Abbott plans to fund the transaction with cash on the balance sheet.
This transaction is subject to shareholder approval of Piramal Healthcare Limited and other customary closing conditions, and is expected to close in the second half of 2010. This transaction is being conducted by a wholly-owned subsidiary of Abbott, resulting in full ownership of the assets of Piramal's Healthcare Solutions business (Domestic Formulations).
Abbott Conference Call
Abbott will conduct a special conference call today at 7:30 a.m. Central time (8:30 a.m. Eastern time) to provide an overview of the transaction. The live Web cast will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com.
For more information on today's announcement, please go to Abbott's press kit at /PHSMediaKit.
About the Piramal Group
The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover exceeded US $1 billion in FY2010.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

ーーーーーーーーーーーーーーー

May 11, 2010　Abbott

Abbott Accelerates Emerging Markets Pharmaceutical Leadership With Zydus Cadila Collaboration; Separately Creates Stand-Alone Established Products Division

Abbott licenses 24 Zydus pharmaceutical products for 15 high-growth emerging markets; holds option for more than 40 additional products
Abbott also announces the creation of new stand-alone Established Products Division with $5 billion in current pharmaceutical sales; business focused on fast-growing emerging markets
Emerging markets expected to grow at three times the rate of developed markets, accounting for 70 percent of global pharma industry growth in next several years


Further strengthening its global competitive position, Abbott today announced a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets, enabling the company to further accelerate its emerging markets growth.

Abbott also announced the formal creation of a stand-alone Established Products Division (EPD) concentrated on expanding the market for Abbott's established pharmaceutical portfolio outside of the U.S., particularly focused in emerging markets. EPD will be led by Michael J. Warmuth, an Abbott leader with significant experience in Abbott's pharmaceutical business, who most recently led Abbott's Diagnostics Division.

"Our new Established Products Division, with $5 billion in sales, will focus on expanding our presence and product offerings in the world's fastest-growing emerging markets," said Olivier Bohuon, executive vice president, Pharmaceutical Products Group, Abbott. EPD is part of the Pharmaceutical Products Group reporting to Bohuon.

Abbott's growing portfolio of established products consists of branded generics - products that have significant brand equity in many international markets - providing durable, sustainable franchises for future growth. This complements Abbott's successful proprietary products business and proprietary pharmaceutical pipeline.

The Zydus Cadila Collaboration

Under the Zydus agreement, Abbott will gain rights to at least 24 Zydus products in 15 key emerging markets where Abbott has a strong and growing presence. The agreement also includes an option for the addition of more than 40 Zydus products to the collaboration.

"The Zydus agreement complements our established products strategy, augmenting this business with a broad portfolio of branded generics," said Bohuon.

The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases. The partnership will leverage Abbott's powerful emerging markets infrastructure to commercialize the Zydus products, with product launches beginning in early 2012.

"We have always believed in working with partners for win-win alliances that look at new opportunities for growth and expansion," said Chairman and Managing Director Zydus Cadila, Pankaj R. Patel. "In this alliance we see tremendous opportunity to participate in multiple ways in a market that is growing and expanding rapidly. Building on our mutual strengths we are creating a considerable competitive advantage for value creation for both partners over the long term."

The financial terms of the agreement were not disclosed.
Abbott's Established Products Strategy

Abbott's new Established Products Division will market Abbott's established products portfolio outside of the U.S., with a focus on accelerating growth in emerging markets.

Throughout the past decade, Abbott has built a leading portfolio of branded generics, through its own products as well as those acquired with the 2001 acquisition of Knoll's pharmaceutical business. In 2007, the company established a separate business unit within its international pharmaceutical division dedicated to established products.

Additionally, a new geographic region focused on Russia, India and China was created which resulted in the doubling of Abbott's growth rate in those countries.

Most recently, the company acquired Solvay Pharmaceuticals, obtaining a diverse branded generics portfolio and providing significant critical mass in key emerging markets.

As a result of these combined actions, Abbott is now among the leading multi-national health care companies in numerous emerging markets. Approximately 20 percent of Abbott's pharmaceutical sales today are in emerging markets.
Emerging Markets Opportunity

Pharmaceutical sales in emerging markets are expected to grow at three times the rate of developed markets and account for 70 percent of the industry's growth over the next several years. Branded generics represent the most significant growth opportunity in emerging markets. Today, branded generics account for 25 percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products.
About Zydus Cadila

Zydus Cadila is an innovative global pharmaceutical company that discovers, develops,manufactures and markets a broad range of healthcare therapies. With an aim to be a research-based pharmaceutical company by 2020, Zydus Cadila invests nearly 8 percent of its turnover on research annually. The group employs over 11,000 people worldwide and is dedicated to improving people's lives.

Additional information about Zydus is available at http://www.zyduscadila.com.
About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

2014年 07月 15日 ロイター   

米 MylanがAbbottの一部事業を買収、税負担も軽減
 
米ジェネリック（後発）医薬品メーカーのマイランは、米医薬品大手、アボット・ラボラトリーズが保有する米国外の先進国市場における特殊・ブランデッド（承継）ジェネリック事業について、約53億ドル相当の株式で買収すると発表した。(ジェネリックメーカーが、 長期収載品を新薬メーカーから、 ブランドをそのまま引き継いで生産・販売する医薬品)

発表を受け、マイランの株価は１４日終値が２．１％上昇。アボット株は１．３％高となった。

合意によると、アボットはオランダで設立される新会社に欧州や日本、カナダ、オーストラリア、ニュージーランドにある資産を移し、マイランが新会社の部門と統合する。マイランは、法人を軽課税国に置いて税負担を軽くすることも可能になるという。

マイランは買収により、消化薬のクレオンや鎮痛薬のブルフェン、インフルエンザワクチンなど、年間売上高で約２０億ドル相当の事業を獲得することになる。

アボットは新会社の株式1億500万株を受け取るが、これを比較的早期に売却してさらなる医療機器事業買収や自社株買いなどの資金に充当していく方針。力強い成長が見込める新興国市場では引き続き、自社でブランデッドジェネリック事業を展開していくとしている。

---

July 14, 2014 Abbott

Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan

        Abbott will retain its branded generics pharmaceuticals business in emerging markets
        Transaction expected to positively impact Abbott's sales and ongoing earnings-per-share growth rates

2016/9/20   Johnson & Johnson、Abbott Medical Optics を買収　

Abbottは事業の「選択と集中」を加速させ、循環器系の医療器具や診断分野に経営資源を集中させる。

　

April 28, 2016

Abbott to Acquire St. Jude Medical

COMBINATION WILL CREATE A PREMIER MEDICAL DEVICE LEADER AND STRENGTHEN ABBOTT'S LONG-TERM GROWTH POTENTIAL
- Acquisition will enhance Abbott's global scale and capabilities and will further diversify its portfolio of best-in-class products and revenue sources
- Combined portfolio will include top positions in high-growth markets and an industry-leading pipeline
- Transaction expected to be accretive to Abbott's adjusted earnings per share(1) in the first full year after closing and increasing thereafter

Abbott and St. Jude Medical, Inc. announced today a definitive agreement for Abbott to acquire St. Jude Medical, creating a premier medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure as well as a leading position in the high-growth neuromodulation market. Under the agreement, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share. At an Abbott stock price of $43.93(2), this represents a total transaction equity value of $25 billion. The combined company will have an industry-leading pipeline expected to deliver a steady stream of new medical device products across cardiovascular, diabetes, vision and neuromodulation patient care.

St. Jude Medical's strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management complement Abbott's leading positions in coronary intervention and transcatheter mitral repair. Together, the company will compete in nearly every area of the cardiovascular market and hold the No. 1 or 2 positions across large and high-growth cardiovascular device markets. This best-in-class combined portfolio will have the depth, breadth and innovation to help patients restore their health, reduce costs for payors and deliver greater value to customers.

"Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position," said Miles D. White, chairman and chief executive officer, Abbott. "The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for health care systems around the world."

"Today's announcement is an exciting next chapter for St. Jude Medical, bringing together two industry leaders with a shared passion for innovation, culture and patients," said Michael T. Rousseau, St. Jude Medical president and chief executive officer. "Our combined scale will expand the global reach, competitiveness and impact of our medical device innovation for physicians and hospitals. This transaction provides our shareholders with immediate value and the opportunity to participate in the significant upside potential of the combined organization. I'd like to thank our 18,000 employees whose hard work and commitment help us deliver leading medical technologies to patients around the world."

The acquisition of St. Jude Medical will advance Abbott's strategic and competitive positions:

Aligned with healthcare and demographic trends: Cardiovascular medical devices are important tools to address the growing health and economic burden of cardiovascular disease (CVD). In the U.S. alone, more than 40 percent of adults are expected to have one or more forms of CVD by 2030. The combined business will have one of the broadest portfolios of devices and an industry-leading pipeline to help healthcare systems provide better care for patients while increasing efficiencies and reducing costs.

Leadership positions in core businesses: With combined annual sales of approximately $8.7 billion, Abbott's cardiovascular business and St. Jude Medical will hold the No. 1 or 2 positions across large and high-growth cardiovascular device markets and will compete in nearly every area of the market – with an aggregate market opportunity of $30 billion.

Well-managed diversity to deliver reliable, sustainable growth: St. Jude Medical further diversifies and enhances sources of future growth for Abbott – the combined pipelines are expected to bring numerous new medical device products to key markets this year, including:

St. Jude Medical's EnSite Precision™ next-generation cardiac mapping system used to visualize and navigate catheters in the heart during ablation procedures; first-to-market MultiPoint™ Pacing technology advances quadripolar technology and provides additional options for cardiac resynchronization therapy patients who are not responsive to other pacing options; Proclaim™ Elite recharge-free Spinal Cord Stimulation System and Prodigy™ Chronic Pain System, which are used for treating chronic pain and are MRI safe, upgradeable, and feature its proprietary Burst technology.
Abbott's FreeStyle® Libre, a sensor-based glucose monitoring system for people with diabetes that eliminates routine finger sticks; Tecnis® Symfony, a first-in-kind continuous range of vision intraocular lens for the treatment of people with cataracts; and Absorb™, the world's first bioresorbable coronary stent.

Strong positions in the world's largest and fastest-growing geographies: St. Jude Medical has strong and leading positions around the world, strengthening Abbott's global scale, infrastructure and capabilities.

Financial Impact of Transaction
The acquisition of St. Jude Medical is expected to be accretive to Abbott's adjusted earnings per share in the first full year after closing and increasing thereafter, with approximately 21 cents of accretion in 2017 and 29 cents in 2018.(1) The combination is anticipated to result in annual pre-tax synergies of $500 million by 2020, including both sales and operational benefits. One-time deal-related costs and integration costs will be provided at a future date.

St. Jude Medical's net debt of approximately $5.7 billion will be assumed or refinanced by Abbott. Abbott intends to fund the cash portion of this transaction with medium- and long-term debt.

The transaction, which has been approved by the boards of directors of St. Jude Medical and Abbott, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including specified regulatory approvals. The transaction is expected to close in the fourth quarter of 2016.

Separate Equity Issuance to Balance Capital Structure
Separately, Abbott expects to issue $3 billion of common stock in the secondary market to rebalance its capital structure, with timing to be determined.

Financing for the St. Jude Medical transaction and the previously announced Alere Inc. acquisition contemplates financing capacity to close both transactions.

米医薬品・医療器具大手のアボット・ラボラトリーズは、米医療機器メーカーのセント・ジュード・メディカルを総額約250億ドル（約２兆7000億円）で買収すると発表した。需要拡大が見込める心血管治療分野を強化する。2016年10〜12月期中の手続き完了を見込む。

アボットはセント・ジュード１株につき、現金46.75ドルとアボット0.8708株、１株当たり85ドル相当を支払う。

セント・ジュードは年間売上高は約59億ドル、従業員数は約１万8000人。ペースメーカーや血管を広げて血流を助けるカテーテル器具など、心血管治療関連の医療器具で業界大手。

アボットの医療器具事業は年間売上高が50億ドル。そのうち30億ドル程度を心血管治療関連が占める。同社は米国など主要市場で肥満や高齢化により同分野の医療用品の需要が伸びると見ており、セント・ジュード取り込みで品ぞろえを強化する。

セント・ジュード・メディカルについて
セント・ジュード・メディカルは、世界中の患者様の命を救い生活を改善する費用対効果の高い医療技術開発することで、最も治療費のかかり、蔓延する疾患への治療に変革をもたらすことに取り組むグローバル医療機器メーカーです。「カーディアック・リズム・マネジメント（不整脈疾患の診断及び治療に用いる医療機器）」、「心房細動」、「心臓血管」、および「ニューロ・モジュレーション（慢性疼痛・神経障害）」の4つの分野に注力しています。米国ミネソタ州セントポールに本社を置き、全世界で事業を展開するグローバル企業です。日本では東京都港区の本社ならびに日本全国に営業拠点を置き、日本で35年以上にわたり患者様の疾患治療に最新のテクノロジーとソリューションを提供しています。

---

昨年、セント・ジュードはThoratecを買収した。アボットは実質的に2社を統合することになるのです。

2015 年 10 月 8 日

セント・ジュード・メディカルがThoratecを買収

2015年10月8日、世界的な医療機器メーカーであるセント・ジュード・メディカルは、重症心不全（HF）治療における補助人工心臓（Mechanical Circulatory Support）技術の世界的リーダーであるThoratecの買収を完了いたしましたので、お知らせいたします。
この買収により、最も広く使用され大規模試験も行われている左心補助人工心臓（LVAD）のHeartMate II®、次世代機器のHeartMate 3™、HeartMate PHP™、およびその他の補助製品が、市場をリードするセント・ジュード・メディカルの心不全製品ラインナップに追加されます。以上の製品を加えることで、セント・ジュード・メディカルは今後、最も包括的な心不全治療用製品ラインを提供して参ります。

買収に関して、セント・ジュード・メディカルのCOOであり、次期社長兼CEOのマイケル・T・ルソーは次のように述べています。「セント・ジュード・メディカルは、心不全治療をリードする2社が統合すること、また現在、心不全分野全体において医師および患者様への革新的ソリューション提供にユニークなポジションを確立している弊社のフランチャイズ展開を推進できることを嬉しく思っております。これを機に、この治療費がかかり、蔓延する疾患の治療に対する世の中の見方が変化していくことを信じています。また、このThoratec社員の皆様を歓迎いたします。」

取得する現金を除いた正味買収金額は約33億米ドルです。買収契約に基づき、買収完了時の発行済みThoratec株式に対して、1株当たり$63.50（利息なし）の現金を受け取る権利が付与されました。セント・ジュード・メディカルは、この買収により、2016年の1株当たりの調整後利益が向上すると予測しています。
必要となる法的な要求事項をすべて満たし、2015年10月7日にThoratecの株主承認を得た後、買収は完了となります。なお、合併完了に伴い、Thoratecの普通株はナスダック市場への上場を廃止します。
セント・ジュード・メディカルの財務顧問はバンクオブアメリカ・メリルリンチ、法律顧問はギブソン・ダン＆クラッチャー法律事務所です。Thoratec社の財務顧問はグッゲンハイム証券会社、法律顧問はレイサム・アンド・ワトキンス法律事務所です。また、センタービュー・パートナーズ社は、買収に関して、Thoratec取締役会に公正な立場から意見提供を行いました。

左心補助人工心臓について
ドナーから提供される心臓が不足していることから、研究者たちは、心不全患者における心室ポンプ機能を助け、心負荷を低減するVADの開発を行ってきました。左室機能を助けるデバイスを左心補助人工心臓（LVAD）といい、右室機能を助ける機器を右心補助人工心臓（RVAD）といいますが、多くの患者様で補助を必要とするのは左室のみであるため、LVADがVAD治療の大半を占めています。
HeartMate II LVADは、患者様自身の心臓の近くに植え込みを行い、弱った左室のポンプ機能を補助する設計となっており、肺から全身へ酸素の豊富な血液を行き渡らせるポンプの機能を担います。また、心不全患者において長期間の心臓補助を行うように設計されており、世界中の試験登録および市販使用により、これまでに21,000例の患者様がHeartMate II VADの植込み手術を受けています。本デバイスは、2008年に移植待機患者を対象として（移植までのブリッジとしての使用（Bridge-To-Transplantation））、また、2010年に心移植の対象ではない患者を対象として（長期在宅治療としての使用（Destination Therapy））米国食品医薬品局（FDA）の承認を受けました。HeartMate II VADの植込み手術は、米国、欧州、日本、アジア太平洋、オーストラリア、カナダおよびラテンアメリカといった世界中の365以上の医療施設で行われています。
HeartMate 3 VADは治験中の長期使用LVADであり、有害事象率を低下させ、外科的留置をより容易にするために設計され磁気浮上型である、Full MagLev™フローテクノロジーを使用しています。本機器は幅広い進行性心不全患者を対象としており、心移植の適応とならない患者様における長期補助使用に関する臨床試験が進行中です。また、移植待機患者を対象とした短期補助についても評価を行う予定です。さらに、2015年第4四半期中には、欧州でCEマークの取得が見込まれています。現在、MOMENTUM 3 U.S. IDE試験の被験者登録が進められています。

　

Mar 27 2020     

FDA grants emergency use authorization for fastest available molecular point-of-care test for novel coronavirus.

Abbott has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.

What makes this test so different is where it can be used: outside the four walls of a traditional hospital such as in the physicians' office or urgent care clinics.

The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOW^TM platform—a lightweight box (6.6 pounds and the size of a small toaster) that can sit in a variety of locations.

Because of its small size, it can be used in more non-traditional places where people can have their results in a matter of minutes, bringing an alternate testing technology to combat the novel coronavirus.

We're ramping up production to deliver 50,000 ID NOW COVID-19 tests per day, beginning next week, to the U.S. healthcare system.

This comes on the heels of our announcement last week of the availability of the Abbott RealTime SARS-CoV-2 EUA test under FDA EUA, which runs on m2000 RealTime molecular system for centralized lab environments. Combined with ID NOW, Abbott expects to produce about 5 million tests in April.

Testing remains a crucial step in controlling the novel COVID-19 pandemic. Continuing to supply healthcare providers with new technologies to help curb the spread of infection is a top priority for public health officials and healthcare providers.

Taking molecular testing to the front lines
Molecular point-of-care testing for COVID-19 offers healthcare workers rapid results in more settings where people show up for care. Molecular testing technologies help detect the presence of a virus by identifying a small section of the virus' genome, then amplifying that portion until there's enough for detection. This process can cut testing wait time from hours, if not days, to as little as five minutes for positive results and 13 minutes for negative results.

When not being used for COVID-19 testing, ID NOW is the leading molecular point-of-care platform for Influenza A&B, Strep A and respiratory syncytial virus (RSV) testing. Our platform holds the largest molecular point-of-care footprint in the U.S. and is already widely available in physicians' offices, urgent care clinics, and hospital emergency departments across the country.

"Through the incredible work of teams across Abbott, we expect to deliver 50,000 COVID-19 tests per day to healthcare professionals on the front lines, where testing capabilities are needed most," said Chris Scoggins, senior vice president, Rapid Diagnostics, Abbott. "Portable molecular testing expands the country's capacity to get people answers faster."

The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.